Overview

Ipsogen is biochip design company that uses a technology platform incorporating high-throughput gene expression analysis facilities for predicting the onset of cancer and the behavior of the disease during treatment. The platform is designed to identify genes that characterize tumor biology at the individual level, enabling clinicians to apply existing and new treatments more efficiently.

Founded in 1999, the company aims to generate products in the fields of diagnostic oncology and pharmacogenomics, as well as offering services to the biopharmaceutical industry. The company is focusing on tests for leukemia and breast cancer as its first products.

The company's scientific know-how is based on a collaboration with the Paoli-Calmettes Institute, one of France's leading cancer centers, also based in Marseille, including exclusive rights in the areas of breast cancer and hemopathies.

Ipsogen is setting up new laboratories in larger premises.

Ipsogen completed in July 2001 a second funding round in which it raised EUR4.5 million (US$3.9 million) from three Paris-based venture capital funds.